3.8 NSC-Exos inhibits the activation of TLR4/NF-κB signaling
pathway
TLR4/NF-κB pathway plays an important role in mediating inflammatory
diseases. To investigate whether the treatment of stroke with NSC-Exos
affects the TLR4/NF-κB pathway, we examined the expression of related
genes and proteins in this pathway. The results showed that the
expression of TLR4 and NF-κB increased, while the expression of P-NF-κB
decreased after cerebral ischemia-reperfusion injury
(P< 0.05). After NSC-Exos transplantation, the
expression of TLR4 and NF-κB decreased, while the expression of P-NF-κB
was weaker (P< 0.05, Fig. 8a,b,c), and the same qPCR
results also verified the experimental results (Fig. 8d). However, the
inhibitor TAK-242 reversed the protective effect of the NSC-Exos
intervention, possibly by regulating the polarization of microglia
phenotypes via the TLR4/NF-κB pathway. There was no significant
difference between TAK-242 group and NSC-Exos group
(P >0.05). In conclusion, our study suggests that
NSC-Exos therapy can effectively inhibit the activation of TLR4/NF-κB
pathway, thereby regulating microglial polarization and reducing the
release of inflammatory cytokines.